Ascendis Pharma A (ASND) Long-Term Investments (2018 - 2026)

Ascendis Pharma A has reported Long-Term Investments for 9 years, with the latest figure at $27.6 million in Q1 2026.

• Quarterly Long-Term Investments fell 35.95% year-over-year to $27.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $27.6 million (down 35.95% YoY) and the FY2025 annual result came in at $37.9 million, up 161.0% from the prior year.
• Long-Term Investments eased to $27.6 million in Q1 2026 per ASND's latest filing, from $37.9 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $43.1 million in Q1 2025 and troughed at $6.1 million in Q4 2023.
• A 5-year average of $26.4 million and a median of $26.9 million in 2024 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments surged 300.76% in 2022, then plunged 73.85% in 2023.
• Over 5 years, Long-Term Investments stood at $23.4 million in 2022, then slumped by 73.85% to $6.1 million in 2023, then soared by 137.11% to $14.5 million in 2024, then jumped by 161.0% to $37.9 million in 2025, then fell by 27.15% to $27.6 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $27.6 million, $37.9 million, and $33.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.